

Camilla Evangelisti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8871674/publications.pdf>

Version: 2024-02-01

81
papers

8,092
citations

93792

39
h-index

75989

78
g-index

82
all docs

82
docs citations

82
times ranked

13992
citing authors

#	ARTICLE	IF	CITATIONS
1	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 1263-1284.	1.9	1,858
2	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. <i>Aging</i> , 2011, 3, 192-222.	1.4	520
3	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. <i>Oncotarget</i> , 2011, 2, 135-164.	0.8	509
4	Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 911-928.	3.3	295
5	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. <i>Oncotarget</i> , 2012, 3, 1068-1111.	0.8	279
6	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. <i>Oncotarget</i> , 2012, 3, 954-987.	0.8	244
7	Current treatment strategies for inhibiting mTOR in cancer. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 124-135.	4.0	234
8	Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. <i>Leukemia</i> , 2011, 25, 1080-1094.	3.3	232
9	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. <i>Oncotarget</i> , 2010, 1, 89-103.	0.8	227
10	Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. <i>Leukemia</i> , 2011, 25, 1064-1079.	3.3	190
11	Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. <i>Leukemia</i> , 2007, 21, 427-438.	3.3	170
12	The emerging multiple roles of nuclear Akt. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 2168-2178.	1.9	165
13	Activity of the Novel Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 against T-Cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2010, 70, 8097-8107.	0.4	152
14	Intranuclear 3 α -phosphoinositide metabolism and Akt signaling: New mechanisms for tumorigenesis and protection against apoptosis?. <i>Cellular Signalling</i> , 2006, 18, 1101-1107.	1.7	121
15	Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside. <i>Current Medicinal Chemistry</i> , 2007, 14, 2009-2023.	1.2	116
16	Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells. <i>Current Medicinal Chemistry</i> , 2011, 18, 2715-2726.	1.2	109
17	Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. <i>Oncotarget</i> , 2012, 3, 371-394.	0.8	109
18	The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 991-1002.	1.9	106

#	ARTICLE	IF	CITATIONS
19	Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. <i>Leukemia</i> , 2008, 22, 147-160.	3.3	105
20	Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1333-1349.	1.9	104
21	Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 449-463.	1.9	104
22	Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2011, 25, 781-791.	3.3	91
23	Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells. <i>Cancer Research</i> , 2008, 68, 9394-9403.	0.4	84
24	The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. <i>Leukemia</i> , 2007, 21, 886-896.	3.3	81
25	Targeting the RAF/MEK/ERK, PI3K/AKT and P53 pathways in hematopoietic drug resistance. <i>Advances in Enzyme Regulation</i> , 2007, 47, 64-103.	2.9	77
26	Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 2336-2342.	3.3	76
27	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. <i>Leukemia</i> , 2014, 28, 543-553.	3.3	74
28	Autophagy in acute leukemias: A double-edged sword with important therapeutic implications. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 14-26.	1.9	74
29	Therapeutic targeting of CK2 in acute and chronic leukemias. <i>Leukemia</i> , 2018, 32, 1-10.	3.3	74
30	Nuclear protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2006, 1761, 542-551.	1.2	72
31	Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance. <i>Leukemia</i> , 2008, 22, 2080-2090.	3.3	70
32	Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2011, 226, 822-831.	2.0	59
33	Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. <i>Oncotarget</i> , 2012, 3, 811-823.	0.8	58
34	Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1229-1244.	1.1	47
35	Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway. <i>Journal of Hematology and Oncology</i> , 2016, 9, 114.	6.9	47
36	Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. <i>British Journal of Haematology</i> , 2005, 130, 716-725.	1.2	43

#	ARTICLE	IF	CITATIONS
37	Nuclear diacylglycerol kinase is a negative regulator of cell cycle progression in C2C12 mouse myoblasts. <i>FASEB Journal</i> , 2007, 21, 3297-3307.	0.2	41
38	Advances in Targeting Signal Transduction Pathways. <i>Oncotarget</i> , 2012, 3, 1505-1521.	0.8	41
39	The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. <i>Cancers</i> , 2010, 2, 1576-1596.	1.7	40
40	Targeting Wnt/ β -catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2020, 235, 5413-5428.	2.0	40
41	Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2012, 18, 1784-1795.	0.9	39
42	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF- κ B. <i>Oncotarget</i> , 2016, 7, 1323-1340.	0.8	39
43	The Role Played by Wnt/ β -Catenin Signaling Pathway in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1098.	1.8	38
44	Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 729-742.	1.5	37
45	Nuclear inositol lipid metabolism: More than just second messenger generation?. <i>Journal of Cellular Biochemistry</i> , 2005, 96, 285-292.	1.2	36
46	Assessment of the effect of sphingosine kinase inhibitors on apoptosis, unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics. <i>Oncotarget</i> , 2014, 5, 7886-7901.	0.8	36
47	Erucylphosphocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms. <i>Leukemia</i> , 2010, 24, 687-698.	3.3	34
48	Targeting Signaling Pathways in T-cell acute lymphoblastic leukemia initiating cells. <i>Advances in Biological Regulation</i> , 2014, 56, 6-21.	1.4	34
49	Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. <i>Leukemia</i> , 2016, 30, 2142-2151.	3.3	34
50	Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1878.	1.8	34
51	Subnuclear localization and differentiation-dependent increased expression of DCK-1 in C2C12 mouse myoblasts. <i>Journal of Cellular Physiology</i> , 2006, 209, 370-378.	2.0	33
52	PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015, 6, 10399-10414.	0.8	32
53	Nuclear phosphoinositides and their roles in cell biology and disease. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2011, 46, 436-457.	2.3	30
54	Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia. <i>Cell Cycle</i> , 2014, 13, 2237-2247.	1.3	30

#	ARTICLE	IF	CITATIONS
55	The phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin signaling network and the control of normal myelopoiesis. <i>Histology and Histopathology</i> , 2010, 25, 669-80.	0.5	30
56	The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias. <i>Cancers</i> , 2020, 12, 333.	1.7	29
57	The wide and growing range of lamin B-related diseases: from laminopathies to cancer. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 126.	2.4	29
58	Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia. <i>Journal of Cellular Physiology</i> , 2018, 233, 1796-1811.	2.0	28
59	The Cutting Edge: The Role of mTOR Signaling in Laminopathies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 847.	1.8	27
60	TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase- α -dependent cell cycle arrest. <i>Cellular Signalling</i> , 2009, 21, 801-809.	1.7	26
61	Identification of a functional nuclear export sequence in diacyl glycerol kinase- α . <i>Cell Cycle</i> , 2010, 9, 384-388.	1.3	26
62	Modulation of TGF β 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins. <i>Oncotarget</i> , 2015, 6, 7424-7437.	0.8	25
63	Elevated TGF β 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes. <i>Nucleus</i> , 2018, 9, 337-349.	0.6	25
64	PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: New options for targeted therapy. <i>Advances in Biological Regulation</i> , 2012, 52, 214-227.	1.4	23
65	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. <i>Advances in Enzyme Regulation</i> , 2008, 48, 113-135.	2.9	20
66	Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review). <i>International Journal of Oncology</i> , 2014, 45, 909-918.	1.4	20
67	Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 1322-1337.	1.9	20
68	GSK-3: a multifaceted player in acute leukemias. <i>Leukemia</i> , 2021, 35, 1829-1842.	3.3	20
69	DGK α is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. <i>Cellular Signalling</i> , 2012, 24, 1573-1582.	1.7	19
70	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. <i>Advances in Biological Regulation</i> , 2019, 74, 100649.	1.4	17
71	Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 921-936.	1.5	15
72	PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines. <i>Oncotarget</i> , 2017, 8, 23213-23227.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment. <i>Advances in Biological Regulation</i> , 2013, 53, 146-155.	1.4	14
74	Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. <i>Cells</i> , 2020, 9, 774.	1.8	14
75	B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?. <i>Cancers</i> , 2020, 12, 3498.	1.7	11
76	GSK-3 β : A key regulator of breast cancer drug resistance. <i>Cell Cycle</i> , 2014, 13, 697-698.	1.3	8
77	The Phosphoinositide 3-Kinase (PI3K)/AKT Signaling Pathway as a Therapeutic Target for the Treatment of Human Acute Myeloid Leukemia (AML). <i>Current Signal Transduction Therapy</i> , 2007, 2, 246-256.	0.3	3
78	The PI3K/Akt/mTOR Pathway. , 2016, , 128-135.		2
79	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
80	3232 Synergistic cytotoxic effects of bortezomib and ck2 inhibitor cx-4945 in acute lymphoblastic leukemia: turning off the prosurvival er chaperone BIP/GRP78 and turning on the proapoptotic NF- κ B. <i>European Journal of Cancer</i> , 2015, 51, S659-S660.	1.3	1
81	Cell Communication: Intracellular Pathways â€œ The PI3K/Akt/mTOR Pathway. , 2022, , .		0